• Trials conducted for medicines, vaccines, and medical devices for indications that have been approved in the US and/or EU.
• Trials conducted for medicines, vaccines, and medical devices that have been terminated (i.e. development for all indications has been discontinued).

• Patient privacy – For example, the request seeks clinical data for which patient de-identification is difficult or for which there is a reasonable likelihood of re-identification, or where there are limitations or restrictions due to privacy rights of individuals in accordance with applicable privacy laws.
• Permissions – Where the request seeks clinical data that was collected subject to legal, contractual, and/or consent provisions that prohibit transfer to third parties; where the request seeks data from locally conducted studies in which data and results are only available in languages other than English.
• Where the request is for case narratives, documentation for adjudication, imaging data (e.g. x-rays, MRI scans, etc.), genetic data and exploratory biomarker data.
• Where there are substantial practical constraints to providing access via the Vivli platform.
• Data will not be provided to requesters with potential or actual conflicts of interest, including individuals requesting access for commercial, competitive or legal purposes.

Research teams must include a biostatistician.

🗹 De-identified Individual Patient Data (IPD)

🗹 Protocol

🗹 Statistical analysis plan

🗹 Data dictionary

🗹 Annotated case report forms

🗹 Redacted clinical study reports

🗹 Analytic code

• Is the research question clearly defined with a scientifically valid rationale?
• Is there a well-documented and rigorous statistical analysis plan?
• If the proposal includes combining data across different Pfizer trials, is there a clear plan to standardize data sets to ensure they are comparable?
• Is there an adequate publication plan to disseminate findings in a peer reviewed journal or scientific meeting?
• Has the applicant certified that the stated research purpose has been declared fully and openly and that the research as described will be conducted and reported in good faith?
• Is the applicant willing to declare all professional interests, affiliations, possible conflicts of interest, and all sources of support for the research as part of the dissemination of their results?
• Does the research team have sufficient expertise and qualifications to perform the proposed investigation?

Synopses will be posted for trials either initiated after Sept. 27, 2007, or trials initiated on or before that date that were still ongoing as of Dec. 26, 2007.

To access the synopses that have been posted to date, please visit https://www.pfizer.com/science/research_clinical_trials/trial_results.

The basic data sets researchers will access may look different from those submitted to regulators or used in publication(s) due to de-identification. As such, in some cases, researchers may not be able to completely duplicate the results of Pfizer analyses.